Gene editing therapy shares largely jumped on two linked catalysts: fresh data exposure at the European Society of Gene and Cell Therapy (ESGCT) annual congress and renewed regulatory clarity from the FDA’s draft guidance on individualized genome editing products. Coverage of the week’s market moves said developers at ESGCT in Hamburg delivered multiple positive presentations, reinforcing clinical momentum. Separately, the FDA draft guidance introduced a structured approach for personalized genome editing submissions, including its Individualized Feature Space concept and expectations for BLA and postapproval management. The agency is soliciting public comment through Nov. 27. Analysts characterized the FDA draft as constructive for the sector by offering a clearer regulatory framework for how individualized edits can fit within a single approval pathway—an issue that has historically been a valuation overhang for the category.